{name}
{subtitle}
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
city
~25 mi. (Milano, Italy, +192 more cities)
facility
Fondazione IRCCS Istituto Nazionale dei Tumori
biomarker
ER Positive, +1 more biomarker
drug
abemaciclib, +1 more drug
drug type
hormone therapy, +1 more type
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
city
~25 mi. (Milano, Italy, +89 more cities)
facility
Ospedale San Raffaele-Oncologia Medica ( Site 1110)
biomarker
ER Positive, +2 more biomarkers
drug
capecitabine, +4 more drugs
drug type
chemotherapy, +1 more type
A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer
city
~25 mi. (Milano, Italy, +383 more cities)
facility
Istituto Europeo Di Oncologia
biomarker
ER Negative, +2 more biomarkers
drug
atezolizumab, +4 more drugs
drug type
chemotherapy, +1 more type
Investigation of Radium-223 Dichloride (Xofigo), a Treatment That Gives Off Radiation That Helps Kill Cancer Cells, Compared to a Treatment That Inactivates Hormones (New Antihormonal Therapy, NAH) in Patients With Prostate Cancer That Has Spread to the Bone Getting Worse on or After Earlier NAH
city
~25 mi. (Milano, Italy, +122 more cities)
facility
IRCCS Istituto Europeo di Oncologia s.r.l. (IEO)
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
city
~25 mi. (Milano, Italy, +130 more cities)
facility
Ospedale San Raffaele ( Site 0362)
drug
BCG solution, +1 more drug
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)
city
~25 mi. (Milano, Italy, +163 more cities)
facility
Ospedale San Raffaele-Oncologia Medica ( Site 0561)
drug
cystectomy, +2 more drugs
drug type
chemotherapy, +3 more types
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
city
~25 mi. (Milano, Italy, +260 more cities)
facility
Ospedale San Raffaele; Medical Oncology, +1 more facility
biomarker
ERBB2 Amplification, +1 more biomarker
drug type
immunotherapy, +1 more type
A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)
city
~25 mi. (Milano, Italy, +115 more cities)
facility
Ospedale San Raffaele; Medical Oncology, +1 more facility
biomarker
ERBB2 Amplification, +7 more biomarkers
drug type
immunotherapy, +1 more type